Related Experiment Video

Updated: Jul 11, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Preclinical characterization of selective estrogen receptor beta agonists: new insights into their therapeutic

H A Harris1

  • 1Wyeth Research, Women's Health Research Institute, 500 Arcola Rd, RN-3163, 19426 Collegeville PA, USA. harrish@wyeth.com

Ernst Schering Foundation Symposium Proceedings
|September 11, 2007
PubMed

Insights

Researchers explored estrogen receptor beta (ERbeta) selective agonists, finding potential therapeutic applications for inflammatory conditions like IBD and arthritis without typical estrogenic side effects.

Area of Science:

  • Endocrinology and pharmacology
  • Molecular biology
  • Drug discovery

Background:

  • Estrogen receptor beta (ERbeta) discovery over a decade ago.
  • Distinguishing ERbeta functions from ERalpha.
  • ERbeta as a potential drug target for various diseases.

Purpose of the Study:

  • To summarize data on three ERbeta selective agonists: ERB-041, WAY-202196, and WAY-200070.
  • To highlight the therapeutic potential of ERbeta agonists.
  • To demonstrate potential applications without classic estrogenic side effects.

Main Methods:

  • Utilizing subtype selective agonists to investigate ERbeta activity.
  • Summarizing illustrative data from preclinical or clinical studies (details not specified in abstract).
  • Comparing the effects of ERB-041, WAY-202196, and WAY-200070.

Main Results:

  • ERbeta agonists show promise for treating inflammatory conditions.
  • Potential applications include inflammatory bowel disease, rheumatoid arthritis, endometriosis, and sepsis.
  • ERbeta agonists may offer therapeutic benefits without uterine stimulation.

Conclusions:

  • ERbeta selective agonists represent a promising therapeutic strategy.
  • These compounds may provide treatments for inflammatory and autoimmune diseases.
  • Targeting ERbeta offers a way to achieve therapeutic effects with reduced side effects.

More Related Videos

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...